Are Parkinson disease patients protected from some but not all cancers?

Neurology

Volumn 69, Issue 15, 2007, Pages 1542-1550

  Inzelberg, Rivka ^a,b   Jankovic, Joseph ^c  

^a MEIR MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; COMPLEMENTARY DNA; HEAT SHOCK PROTEIN 70; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 6Q; DISEASE ASSOCIATION; GENE EXPRESSION; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; MELANOMA; NEUROBLASTOMA; ONCOGENE; PARKIN GENE; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 35148865254     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000277638.63767.b8     Document Type: Article

References (89)

1. Doshay LJ. Problem situations in paralysis agitans. JAMA 1954;156:680-684.
2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
3. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985;17:505-509.
4. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in Parkinson's disease. Br Med J 1995;310:1500-1501.
5. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer in Parkinson's disease. J Neurol 2000;247:429-434.
6. Gorrell JM, Johnson CC, Rybicki BA. PD and its comorbid disorders. Neurology 1994;44:1865-1868.
7. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-299.
8. Vanacore N, Spila-Alegiani S, Raschetti R, Meco G. Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 1999;52:395-398.
9. Westlund K, Hougen A. Cancer as the cause of death among patients with other chronic diseases. JAMA 1956;162:1003.
10. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic cue? Neurology 1995;45:1041-1051.
11. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson's disease in retrospective studies. Ann Neurol 2001;50:780-786.
12. Hernan MA, Takkaouche B, Caamono-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
13. Tanner CC, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins. Neurology 2002;58:581-588.
14. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 2004;19:614-621.
15. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 2004;27:561-568.
16. Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann Neurol 2005;57:27-33.
17. Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:317-321.
18. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer patterns in patients with Parkinson's disease. Br J Cancer 2005;92:201-205.
19. Elbaz A, Peterson BJ, Yang P, et al. Nonfatal cancer preceding Parkinson's disease. Epidemiology 2002;13:157-164.
20. Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort. Mov Disord 2005;30:719-725.
21. Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006;17:582-587.
22. Constantinescu R, Romer M. Kieburtz, the DATATOP Parkinson Study Group Investigators. Malignant melanoma in early Parkinson's disease-DATATOP trial. Mov Disord 2006;21(suppl 13):S120.
23. Rigel DS, Patel Z, Bolognia J, Eichler C, Ellis DL, Friedman RJ. Evaluation of Parkinson's disease (PD) prevalence in patients with malignant melanoma. Mov Disord 2006;21(suppl 13):S58.
24. Bertoni JM, Arlette JP, Fernandez HH, et al. Parkinson's disease and melanoma: an epidemiologic evaluation. Ann Neurol 2006(suppl 3):S71-S72.
25. Olsen JH. Avoidable cancers in Nordic countries: aims and background. APMIS 1997;76:1-8.
26. Abramson DH, Rubenfeld MR. Choroidal melanoma and levodopa. JAMA 1984;252:1011-1012.
27. Sober AJ, Wick MM. Levodopa therapy and malignant melanoma. JAMA 1978;240:554-555.
28. Sandyk R. Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and the role of the pineal gland. Int J Neurosci 1992;63:137-140.
29. Kincannon J, Boutzale C. The physiology of pigmented nevi. Pediatrics 1999;104:1042-1045.
30. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence. Parkinsonism 2003;9:321-327.
31. Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK. Levodopa therapy and malignant melanoma. Ann Pharmacother 2000;34:382-385.
32. Lieberman AN, Shupack JL. Levodopa and melanoma. Neurology 1974;24:340-343.
33. Woofter MJ, Manyam BV. Safety of long-term levodopa therapy in malignant melanoma. Clin Neuropharmacol 1994;17:315-319.
34. Pfutzner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 1997;37:332-336.
35. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. JNCI 1999;91:629-634.
36. Bellomo G, Santambrogio L, Fiacconi M, Scarpani AM, Ciufettti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol 1991;238:19-22.
37. Gao X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon metamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001;103:385-394.
38. Liu B, Dluzen DE. Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of mice. Neuroendocrinology 2006; 83: 295-302.
39. Obata T. Tamoxifen protect against hydroxyl radical generation induced by phenelzine in rat striatum. Toxicology 2006;222:46-52.
40. D'Astous M, Mickley KR, Dluzen DE, Di Paolo T. Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice). Neuroendocrinology 2005;82:111-120.
41. Tan EK, Jankovic J. Genetic testing in Parkinson's disease: promises and pitfalls. Arch Neurol 2006;63:1232-1237.
42. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
43. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-1567.
44. Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 2006;63:273-277.
45. Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. A family with Parkinson's disease, essential tremor, Bell's palsy and parkin mutations. Arch Neurol 2007;64:421-424.
46. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
47. Lin JC, Scherer SW, Tougas L, et al. Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. Oncogene 1996;13:2001-2008.
48. Tibiletti MG, Trubia M, Ponti E, et al. Physical map of the D6S149-D6S193 region on chromosome 6Q27 and its involvement in benign surface epithelial ovarian tumors. Oncogene 1998;16:1639-1642.
49. Cesari R, Martin EC, Calin GA, et al. .Parkin a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27 Proc Natl Acad Sci 2003;100:5956-5961.
50. Denison SR, Wang F, Becker NA, et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 2003;22:8370-8378.
51. Picchio MC, Martin ES, Cesari R, et al. Alterations of the tumor suppressor gene parkin in non-small cell lung cancer. Clin Cancer Res 2004;10:2720-2724.
52. Wang F, Denison S, Lai JP, et al. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 2004;40:85-96.
53. Kim RH, Mak TW. Tumours and tremors: how PTEN regulation underlies both. Br J Cancer 2006;94:620-624.
54. Zimprich A, Biksup S, Leitner P, et al. Mutations in LRRK2 cause autosomal dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
55. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK-8-linked Parkinson's disease. Neuron 2004;44:595-600.
56. Deng H, Le W, Guo Y, et al. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005;57:933-934.
57. Tomiyama H, Li Y, Funayama M, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 2006;12:1102-1108.
58. Deng H, Le W, Guo Y, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 2006;21:102-106.
59. Deng H, Jankovic J, Guo Y, Xie W, Le W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun 2005;337:1133-1138.
60. Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett 2005;579:6716-6720.
61. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
62. Vastag B. HSP-90 inhibitors promise to complement cancer therapies. Nat Biotechnol 2006;24:1307.
63. Duan W, Zhu X, Ladenheim B, Yu QS, et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002;52:597-606.
64. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the -synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
65. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of ovary. Cancer 2000;88:2154-2163.
66. Banner BF, Sonmez-Alpan E, Yousem SA. An immunophenotypic study of the inflammatory cell populations in colon adenomas and carcinomas. Mod Pathol1993;6:295-301.
67. Maraganore DM, Lesnick TG, Elbaz A, et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004;55:512-521.
68. Valente EM, Abou-Seiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;302:1158-1160.
69. Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005;7:263-273.
70. Bonifati V, Rizzu P, Van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2002;299:256-299.
71. Ji H, Liu YE, Jia T, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997;57:759-764.
72. Ninkina NN, Alimova-Kost MV, Paterson JWE, et al. Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet 1998;7:1417-1424.
73. Wu RM, Cheng CW, Chen KH, et al. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese. Neurology 2001;13:375-382.
74. Inoue H, Shibuta K, Matsuyama A, et al. Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer. Oncol Rep 2005;14:707-712.
75. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186-195.
76. Gorrell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders. Neurology 1994;44:1865-1868.
77. Vijayalaxmi Thomas CRJ, Rietr RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002;20:2576-2601.
78. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses Health Study. JNCI 2001;93:563-1568.
79. Mawson AT. Breast cancer in female flight attendants. Lancet 1998;352:626.
80. Schernhammer E, Chen H, Ritz B. Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? Cancer Causes Control 2006;17:577-582.
81. West AB, Dawson VL, Dawson TM. To die or grow: Parkinson's disease and cancer. Trends Neurol Sci 2005;28:348-352.
82. Pritchard PB, Netsky MG. Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 1973;23:215-222.
83. Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol 1983;40:151-154.
84. Rajput AH, Offord KP, Beard M, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology 1987;37:226-232.
85. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
86. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-265.
87. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002;52:549-555.
88. Matsushima-Nishiu M, Unoki M, Ono K, et al. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 2001;61:3741-3749.
89. Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 2001;20:4457-4465.